Selective orthostatic agonist of hFFA2-DREADDs
MOMBA is a selective orthosteric agonist for human free fatty acid 2 (hFFA2) engineered receptors, designer receptors activated by designer drugs (DREADD), it shows no activity to wild-type hFFA2, hFFA3, and mouse FFA2. MOMBA inhibit forskolin-stimulated cAMP levels in cells expressing the hFFA2-DREADD receptor with improved potency and equivalent efficacy to Sorbic acid (Cat. No. 7119). In hFFA2-DREADD transgenic mice, MOMBA treatment significantly reduces gut transit and promotes concentration-dependent release of GLP-1 from colonic crypts. Orally bioavailable.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-151353 |
| Réf. fabricant | 18765855 |
| Nom chimique ou matériau | 4-Methoxy-3-methylbenzoic acid |
| CAS | 6880-04-2 |
| Quantité | 250 mg |
| Cible | DREADD Activators |
| Formule moléculaire | C<sub>9</sub>H<sub>10</sub>O<sub>3</sub> |
| Pureté | 0.98 |
